Nutraveris

Archives

Thursday, May 30, 2019
Category : NEWS, INGREDIENTS, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

Our Artificial Intelligence solutions, developed by our experts, NOL Datasolution to Create & NOL Compliance to Launch your products, inform you :  

 

This double-blind, randomized, placebo-controlled study, evaluated among 92 patients with non-alcoholic fatty liver disease (NAFLD) the effects of supplementation with either 3 g/d of turmeric or 9 g/d of infused chicory seed (4.5 g /100mL) or both turmeric and chicory seed or a placebo during 12 weeks.

Beneficial effects of chicory seedsTurmeric supplementation on the lipid profile and obesity markers

At the end of the supplementation period, results showed a significant decrease in body mass index and waist circumference in chicory and mixture groups (p < 0.05 vs. placebo). Combination of turmeric and chicory seed significantly decreased serum alkaline phosphatase level (p < 0.05). Serum levels of HDL-Cholesterol increased considerably in turmeric and mixture groups (p < 0.05 vs. placebo). Moreover, turmeric and mixture supplementations led to significant reduction in serum levels of triglycerides/HDL-Cholesterol and LDL-Cholesterol/HDL-Cholesterol ratio (p < 0.05 vs. placebo).

In conclusion, turmeric and chicory seed supplementation can be significantly useful in management of NAFLD risk factors.

 

Ghaffari A, Rafraf M, Navekar R, Sepehri B, Asghari-Jafarabadi M, Ghavami SM. Turmeric and chicory seed have beneficial effects on obesity markers and lipid profile in non-alcoholic fatty liver disease (NAFLD). Int J Vitam Nutr Res. 2019 Apr 24:1-10.

 

NUTRAVERIS is the Leading European consultancy on Regulatory & Scientific affairs in Nutrition and Health, founded 13 years ago, to help you formulate, ensure the compliance and substantiation of your products in the 28 EU Member States. 

Thanks to our strong know-how and experience of regulatory compliance, notifications, novel foods, health claims, medical writing,…We, as experts, created Artificial Intelligence solutions, that we use in our everyday missions:
-NOL Datasolution to CREATE new products thanks to Regulatory, Scientific & Marketing data.
-NOL Compliance to LAUNCH products into the different EU member states thanks to automated Compliance analysis, Labeling generation and Monitoring & updating at anytime.

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Tuesday, May 28, 2019
Category : NEWS, INGREDIENTS, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

Our Artificial Intelligence solutions, developed by our experts, NOL Datasolution to Create & NOL Compliance to Launch your products, inform you :  

The aim of this double-blinded, randomized, placebo-controlled and crossover study was to examine the effects of walnut consumption on cardiovascular risk factors and to explore the underlying mechanisms.

Walnut reduces some cardiovascular risk factors in obese subjects.

10 obese subjects have been enrolled and participated in two 5-day periods during which they consumed a placebo smoothie or a walnut-containing smoothie (48 g walnuts per day). Walnut consumption reduced fasting small and dense LDL particles (p < 0.02) and increased pastprandial large HDL particles (p < 0.01). Insulin Resistance Score, glucose and insulin AUC decreased significantly after walnut consumption (p < 0.01, p < 0.02, p < 0.04, respectively). Lipidomic analysis showed a robust reduction in harmful ceramides, hexosylceramides and sphingomyelins, which have been shown to mediate effects on cardiometabolic risk. Peptide YY AUC significantly increased after walnut consumption (p < 0.03).

The authors concluded that walnut consumption may reduce cardiovascular risk, at least in part through the reduction of ceramides and other atherogenic lipids.

 

Tuccinardi D, Farr OM, Upadhyay J, Oussaada SM, Klapa MI, Candela M, Rampelli S, Lehoux S, Lázaro I, Sala-Vila A, Brigidi P, Cummings RD, Mantzoros CS. Mechanisms Underlying the Cardiometabolic Protective Effect of Walnut Consumption in Obese Subjects: A Cross-Over, Randomized, Double-Blinded, Controlled Inpatient Physiology Study. Diabetes Obes Metab. 2019 May 14.

 

NUTRAVERIS is the Leading European consultancy on Regulatory & Scientific affairs in Nutrition and Health, founded 13 years ago, to help you formulate, ensure the compliance and substantiation of your products in the 28 EU Member States.

Thanks to our strong know-how and experience of regulatory compliance, notifications, novel foods, health claims, medical writing,…We, as experts, created Artificial Intelligence solutions, that we use in our everyday missions:

-NOL Datasolution to CREATE new products thanks to Regulatory, Scientific & Marketing data.

-NOL Compliance to LAUNCH products into the different EU member states thanks to automated Compliance analysis, Labeling generation and Monitoring & updating at anytime.

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Thursday, May 23, 2019
Category : NEWS, INGREDIENTS, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

Our Artificial Intelligence solutions, developed by our experts, NOL Datasolution to Create & NOL Compliance to Launch your products, inform you :  

 

Lertal® is an oral nutraceutical containing Perilla frutescens extract, vitamin D3 and quercetin, which has been shown to reduce allergic symptoms in adults. The purpose of this randomized, double-blinded and placebo-controlled study was to evaluate the effects of Lertal® in children with allergic rhinoconjunctivitis.

Effects of a food supplements containing Perilla frutescens, vitamin D3 and quercetin on allergic rhinoconjunctivitis in children.

146 children (9.1 ± 1.88 years) have been enrolled. All participants were treated with standard antihistaminic medication. They were randomly assigned to placebo or to the test product for 4 weeks. The main outcome was the change in Total Symptom Score during the last 12 hours, from baseline to the end of the study.

A reduction in Total Symptom Score has been measured in both groups, without any significant difference between the two groups. However, among the 24 children who experienced symptoms worsening, 8 were in the supplemented group and 16 in the placebo group (p < 0.05). All children with symptoms worsening was poly-allergic children exposed to multiple allergen.

Therefore, this study suggests that Lertal® has no clear effect on treatment of allergic rhinoconjunctivitis in children when used in combination with antihistaminic treatment, but may prevent symptoms worsening in polyallergic chilren.

 

Marseglia GL, Licari A, Ciprandi G, Italian Study Group on Pediatric Allergic Rhinoconjunctivitis. A polycentric, randomized, double blind, parallel-group, placebo-controlled study on Lertal®, a multicomponent nutraceutical, as add-on treatment in children with allergic rhinoconjunctivitis: phase I during active treatment. J Biol Regul Homeost Agents. 2019 Mar-April.33(2):617-622.

 

NUTRAVERIS is the Leading European consultancy on Regulatory & Scientific affairs in Nutrition and Health, founded 13 years ago, to help you formulate, ensure the compliance and substantiation of your products in the 28 EU Member States. 

Thanks to our strong know-how and experience of regulatory compliance, notifications, novel foods, health claims, medical writing,…We, as experts, created Artificial Intelligence solutions, that we use in our everyday missions:

-NOL Datasolution to CREATE new products thanks to Regulatory, Scientific & Marketing data.

-NOL Compliance to LAUNCH products into the different EU member states thanks to automated Compliance analysis, Labeling generation and Monitoring & updating at anytime.

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Tuesday, May 21, 2019
Category : NEWS, REGULATORY | Author : experts | Comment : No Comments
Tags:

Our Artificial Intelligence solutions, developed by our experts, NOL Datasolution to Create & NOL Compliance to Launch your products, inform you :  

Maximum level of citrinin in food supplements based on rice fermented with red yeast Monascus purpureus is currently 2000 µg/kg according to Regulation (EC) 1881/2006.

 

rice fermented with red yeast

A draft regulation that will lower this maximum level for citrinin from 2000 µg/kg to 100 µg/kg has been voted by European Commission and Member States during the Standing Committee on Plants, Animals, Food and Feed – Section Novel Food and Toxicological Safety of the Food Chain on 29 March 2019.

The final text is expected to be published in the coming months.

 

NUTRAVERIS is the Leading European consultancy on Regulatory & Scientific affairs in Nutrition and Health, founded 13 years ago, to help you formulate, ensure the compliance and substantiation of your products in the 28 EU Member States. 

Thanks to our strong know-how and experience of regulatory compliance, notifications, novel foods, health claims, medical writing,…We, as experts, created Artificial Intelligence solutions, that we use in our everyday missions:

-NOL Datasolution to CREATE new products thanks to Regulatory, Scientific & Marketing data.

-NOL Compliance to LAUNCH products into the different EU member states thanks to automated Compliance analysis, Labeling generation and Monitoring & updating at anytime.

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

 +33 2 96 76 54 87

Thursday, May 16, 2019
Category : NEWS, INGREDIENTS, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

Our Artificial Intelligence solutions, developed by our experts, NOL Datasolution to Create & NOL Compliance to Launch your products, inform you :  

 

The aim of this double-blinded, randomized and placebo-controlled study was to examine the effects of an Andrographis paniculata extract in patients with knee osteoarthritis. 103 patients have been enrolled and received a placebo of the extract (ParActin®, 300 or 600 mg/day) for 84 days.

An Andrographis paniculata supplementation reduces joint pain in patients with knee osteoarthritis.

The both doses of supplement have reduced joint pain at days 28, 56 and 84 in comparison to control. Moreover, significant improvements in WOMAC stiffness scores and function scores, as in fatigue score have been measured in both supplemented groups compared to placebo. Finally, quality of life, assessed by the SF-36 questionnaire, and the score of the Functional Assessment of Chronic Illness Therapy have been improved in both supplemented groups.

In conclusion, this study shows that ParActin®, an Andrographis paniculata extract, can reduce joint pain and improve joint function in patients with knee osteoarthritis.

 

Hanckle JL, Srivastav S, Caceres DD, Burgos RA. A double-blind, randomized, placebo-controlled study to asses the efficacy of Andrographis paniculata standardized extract (ParActin®) on pain reduction in subjects with knee osteoarthritis. Phytother Res. 2019 Apr 10.

 

NUTRAVERIS is the Leading European consultancy on Regulatory & Scientific affairs in Nutrition and Health, founded 13 years ago, to help you formulate, ensure the compliance and substantiation of your products in the 28 EU Member States. 

 Thanks to our strong know-how and experience of regulatory compliance, notifications, novel foods, health claims, medical writing,…We, as experts, created Artificial Intelligence solutions, that we use in our everyday missions:

-NOL Datasolution to CREATE new products thanks to Regulatory, Scientific & Marketing data.

-NOL Compliance to LAUNCH products into the different EU member states thanks to automated Compliance analysis, Labeling generation and Monitoring & updating at anytime.

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87